Biomarkers associated with autoimmune diseases of the lung
AssigneeThe Regents of the University of California
InventorsMark S. Anderson, Anthony K. Shum
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease.
Claims22
A method for assessing whether a mammalian patient has or is predisposed to an interstitial lung disease (ILD), said method comprising:
- a) subjecting a biological sample from the patient to a procedure for quantitation of an immune response to a lung autoantigen, wherein the lung autoantigen comprises at least one bactericidal/permeability-increasing protein (BPI) domain, and wherein said procedure comprises an antibody-based assay or a T cell-based assay;
- and
- b) detecting an elevated immune response to said lung autoantigen in said biological sample as compared to a control biological sample, wherein said elevated immune response is associated with presence of the ILD or a predisposition to ILD.
An animal model of interstitial lung disease comprising a mammal immunized with a formulation comprising an adjuvant and a lung autoantigen, wherein the lung autoantigen comprises at least one bactericidal/permeability-increasing protein (BPI) domain.
Dependencies are inferred from the claim text.